NYSE:ZBH - Zimmer Biomet Stock Price, Price Target & More

$115.10 +4.51 (+4.08 %)

(As of 04/26/2018 04:00 PM ET)

Previous Close$110.59

Today's Range$107.69 - $115.23

52-Week Range$104.28 - $133.49

Volume3.07 million shs

Average Volume1.31 million shs

Market Capitalization$22.23 billion

P/E Ratio14.33

Dividend Yield0.88%

Beta1.17

About Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

SymbolNYSE:ZBH

CUSIPN/A

Webwww.zimmerbiomet.com

Phone574-267-6131

Debt

Debt-to-Equity Ratio0.76%

Current Ratio1.50%

Quick Ratio0.81%

Price-To-Earnings

Trailing P/E Ratio14.33

Forward P/E Ratio14.76

P/E Growth1.91

Sales & Book Value

Annual Sales$7.82 billion

Price / Sales2.99

Cash Flow$15.7456 per share

Price / Cash7.31

Book Value$57.96 per share

Price / Book1.99

Profitability

EPS (Most Recent Fiscal Year)$8.03

Net Income$1.81 billion

Net Margins23.51%

Return on Equity15.45%

Return on Assets6.19%

Miscellaneous

Employees18,200

Outstanding Shares203,150,000

How to Become a New Pot Stock Millionaire

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Monday, March 12th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.24 per share on Monday, April 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Wednesday, March 28th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet (NYSE:ZBH) posted its earnings results on Wednesday, April, 25th. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.89 by $0.02. The medical equipment provider earned $2.02 billion during the quarter, compared to analysts' expectations of $1.98 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the company posted $2.13 EPS. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $7.60-$7.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.80. The company issued revenue guidance of $7.94-$8.09 billion, compared to the consensus revenue estimate of $7.96 billion.

What price target have analysts set for ZBH?

23 analysts have issued 1-year target prices for Zimmer Biomet's shares. Their forecasts range from $115.00 to $168.00. On average, they anticipate Zimmer Biomet's stock price to reach $138.80 in the next twelve months. View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:

1. Canaccord Genuity analysts commented, "We are updating our model to reflect Zimmer’s adoption of several previously disclosed new accounting standards (revenue recognition for customer contracts, reporting of pension costs, and hedging activities). The company adopted the changes effective January 1, 2018, and recently provided updated historical financials (for 2016 and 2017) to reflect a retrospective adoption of the new standards. While the new accounting policies have not resulted in any material changes to 2016 and 2017 historical results, we have nonetheless updated our model to reflect how the company will report moving forward. Additionally, we have also tweaked our forward estimates to incorporate a slightly more conservative revenue ramp in 2018/2019 and higher COGS and operating spend related to the quality/manufacturing remediation and sales channel incentives/ investments. Thus we maintain our HOLD rating and lower our price target to $121." (4/12/2018)
2. Cantor Fitzgerald analysts commented, "ZBH received FDA clearance for its Persona cementless knee, earlier than we expected." (2/5/2018)
3. According to Zacks Investment Research, "Zimmer Biomet ended the third quarter 2017 on a dismal note with earnings below the Zacks Consensus Estimate and revenues in line with the same. Sales were declining within most of the core segments primarily due to the slower pace of supply recovery and sales recapture of certain key brands particularly in the United States and softened domestic market conditions. The lowered 2017 guidance also added to our concerns indicating little chances of recovery ahead. Over, the last three months, the company has been observed to trade below the broader industry. Nevertheless, we look forward to the expected synergy from the LDR Holding acquisition, which should broaden and complement the company's musculoskeletal offering. We are also impressed by the strong strategic and financial goals which the combined entity expects to reach, now that the deal has been closed." (11/20/2017)

Who are some of Zimmer Biomet's key competitors?

Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), Smith & Nephew (SNN), Coloplast (CLPBY), William Demant (WILYY), STERIS (STE), Mine Safety Appliances (MSA), Inogen (INGN), Halyard Health (HYH), Wright Medical Group (WMGI), Consort Medical (CSRMY), Invacare (IVC), RTI Surgical (RTIX) and Sientra (SIEN).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:

Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
Dr. Katarzyna Mazur-Hofsaess, Pres of Europe, Middle East & Africa (Age 54)
Mr. Sang Yi, Pres of Asia Pacific (Age 56)
Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)

Has Zimmer Biomet been receiving favorable news coverage?

News stories about ZBH stock have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet earned a media sentiment score of 0.10 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 46.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $115.10.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $22.23 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]

MarketBeat Community Rating for Zimmer Biomet (ZBH)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		594 (Vote Outperform)
Underperform Votes:		466 (Vote Underperform)
Total Votes:		1,060

MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Zimmer Biomet (NYSE:ZBH) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

23 Wall Street analysts have issued ratings and price targets for Zimmer Biomet in the last 12 months. Their average twelve-month price target is $138.80, suggesting that the stock has a possible upside of 20.59%. The high price target for ZBH is $168.00 and the low price target for ZBH is $115.00. There are currently 6 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.78	2.82	2.81	2.59
Ratings Breakdown:	0 Sell Rating(s) 6 Hold Rating(s) 16 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 16 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 15 Buy Rating(s) 1 Strong Buy Rating(s)	2 Sell Rating(s) 6 Hold Rating(s) 13 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$138.80	$140.6316	$137.4211	$136.55
Price Target Upside:	20.59% upside	26.26% upside	10.17% upside	16.62% upside

Zimmer Biomet (NYSE:ZBH) Consensus Price Target History

Price Target History for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/12/2018	Canaccord Genuity	Reiterated Rating	Hold	$121.00	Low
4/2/2018	Evercore ISI	Initiated Coverage	In-Line	$115.00	Low
3/23/2018	Robert W. Baird	Downgrade	Outperform -> Neutral		High
3/15/2018	Oppenheimer	Initiated Coverage	Outperform	$135.00	Low
3/15/2018	Raymond James	Initiated Coverage	Outperform	$135.00	Low
2/27/2018	Citigroup	Lower Price Target	Neutral -> Neutral	$132.00 -> $121.00	Low
2/26/2018	Morgan Stanley	Lower Price Target	Overweight -> Overweight	$150.00 -> $148.00	Low
2/5/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$140.00	High
1/31/2018	Leerink Swann	Boost Price Target	Outperform -> Outperform	$142.00 -> $146.00	Low
1/31/2018	Stifel Nicolaus	Upgrade	Hold -> Buy	$120.00 -> $168.00	Low
1/30/2018	BMO Capital Markets	Reiterated Rating	Buy	$144.00	Low
1/30/2018	Needham & Company LLC	Boost Price Target	Strong-Buy -> Strong-Buy	$144.00 -> $155.00	Medium
1/29/2018	SunTrust Banks	Boost Price Target	Buy	$142.00	Medium
12/19/2017	Goldman Sachs	Upgrade	Sell -> Neutral	$125.00	Low
12/19/2017	Wells Fargo	Upgrade	Market Perform -> Outperform		Low
11/14/2017	Deutsche Bank	Upgrade	Hold -> Buy	$128.00	N/A
11/9/2017	Edward Jones	Upgrade	Hold -> Buy		N/A
11/7/2017	Royal Bank of Canada	Lower Price Target	Outperform	$125.00	N/A
11/3/2017	Jefferies Group	Reiterated Rating	Buy	$136.00	N/A
11/2/2017	Piper Jaffray	Downgrade	Overweight -> Neutral		N/A
8/24/2017	Gabelli	Initiated Coverage	Buy	$142.00	Low
7/14/2017	Bank of America	Reiterated Rating	Buy -> Buy	$158.00	Medium
7/12/2017	Guggenheim	Upgrade	Neutral -> Buy	$157.00	Medium
1/5/2017	JPMorgan Chase	Set Price Target	Buy	$134.00	N/A
12/21/2016	UBS	Downgrade	Neutral -> Sell	$113.00 -> $100.00	N/A
11/8/2016	Northcoast Research	Downgrade	Buy -> Neutral		N/A
9/22/2016	Argus	Reiterated Rating	Buy	$140.00	N/A
8/23/2016	Barclays	Boost Price Target	Overweight	$140.00 -> $145.00	N/A
7/29/2016	JMP Securities	Boost Price Target	Market Outperform	$131.00 -> $145.00	N/A
5/16/2016	Sterne Agee CRT	Reiterated Rating	Buy		N/A

(Data available from 4/26/2016 forward)

Zimmer Biomet (NYSE:ZBH) Earnings History and Estimates Chart

Earnings by Quarter for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) Earnings Estimates

2018 EPS Consensus Estimate: $7.78
2019 EPS Consensus Estimate: $8.21

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	6	$1.85	$1.98	$1.89
Q2 2018	6	$1.85	$1.97	$1.91
Q3 2018	6	$1.73	$1.84	$1.79
Q4 2018	6	$2.13	$2.28	$2.19
Q1 2019	2	$1.98	$2.04	$2.01
Q2 2019	2	$2.00	$2.07	$2.04
Q3 2019	2	$1.87	$1.91	$1.89
Q4 2019	2	$2.26	$2.28	$2.27

Zimmer Biomet (NYSE ZBH) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/26/2018
4/25/2018	Q1 2018	$1.89	$1.91	$1.9805 billion	$2.0180 billion	View	N/A
1/30/2018	Q4 2017	$2.0980	$2.10	$2.0286 billion	$2.0743 billion	View	Listen
11/1/2017	Q3 2017	$1.74	$1.72	$1.8291 billion	$1.8180 billion	View	N/A
7/27/2017	Q2 2017	$2.10	$2.08	$1.9541 billion	$1.9544 billion	View	N/A
4/27/2017	Q1 2017	$2.1110	$2.13	$1.9607 billion	$1.9773 billion	View	N/A
1/31/2017	Q416	$2.11	$2.14	$1.98 billion	$2.01 billion	View	Listen
10/31/2016	Q316	$1.79	$1.79	$950.20 million	$1.83 billion	View	Listen
7/28/2016	Q216	$1.97	$2.02	$1.90 billion	$1.93 billion	View	Listen
4/28/2016	Q116	$1.93	$2.00	$1.88 billion	$1.90 billion	View	Listen
1/28/2016	Q415	$2.04	$2.09	$1.96 billion	$1.98 billion	View	Listen
10/29/2015	Q315	$1.56	$1.64	$1.76 billion	$1.76 billion	View	Listen
7/30/2015	Q2 2015	$1.56	$1.59	$1.1429 billion	$1.1676 billion	View	N/A
4/30/2015	Q115	$1.54	$1.58	$1.15 billion	$1.13 billion	View	N/A
1/29/2015	Q414	$1.71	$0.91	$1.25 billion	$1.22 billion	View	N/A
10/23/2014	Q314	$1.00	$0.96	$1.10 billion	$1.11 billion	View	Listen
7/24/2014	Q214	$1.49	$1.49	$1.21 billion	$1.18 billion	View	N/A
4/24/2014	Q114	$1.47	$1.50	$1.18 billion	$1.16 billion	View	Listen
1/31/2014	Q114	$1.62	$1.36	$1.22 billion	$1.24 billion	View	N/A
10/24/2013	Q313	$1.24	$1.25	$1.06 billion	$1.07 billion	View	N/A
7/25/2013	Q2 2013	$1.44	$1.43	$1.15 billion	$1.17 billion	View	N/A
4/25/2013	Q1 2013	$1.40	$1.41	$1.14 billion	$1.14 billion	View	N/A
1/31/2013	Q4 2012	$1.49	$1.51	$1.17 billion	$1.18 billion	View	N/A
10/25/2012		$1.13	$1.15			View	N/A
7/26/2012		$1.32	$1.34			View	N/A
4/26/2012		$1.30	$1.30			View	N/A
1/26/2012		$1.34	$1.36			View	N/A
10/27/2011		$1.03	$1.04			View	N/A
7/27/2011		$1.19	$1.21			View	N/A
4/28/2011		$1.12	$1.19			View	N/A
1/27/2011		$1.19	$1.21			View	N/A
10/28/2010	Q3 2010	$0.95	$0.96			View	N/A
7/22/2010	Q2 2010	$1.05	$1.09			View	N/A
4/22/2010	Q1 2010	$1.01	$1.02			View	N/A
1/28/2010	Q4 2009	$1.08	$1.12			View	N/A
10/22/2009	Q3 2009	$0.85	$0.88			View	N/A
7/23/2009	Q2 2009	$0.96	$1.01			View	N/A
4/23/2009	Q1 2009	$0.94	$0.95			View	N/A
1/29/2009	Q4 2008	$1.00	$1.00			View	N/A
10/23/2008	Q3 2008	$0.89	$0.97			View	N/A
7/22/2008	Q2 2008	$1.03	$1.03			View	N/A
4/24/2008	Q1 2008	$1.04	$1.04			View	N/A
1/29/2008	Q4 2007	$1.04	$1.18			View	N/A

(Earnings results data provided by Zacks Investment Research)

Zimmer Biomet (NYSE:ZBH) Dividend Information

Zimmer Biomet pays an annual dividend of $0.96 per share, with a dividend yield of 0.83%. ZBH's next quarterly dividend payment will be made on Monday, April 30. Zimmer Biomet pays out 11.96% of its earnings out as a dividend.

Next Dividend:	4/30/2018
Annual Dividend:	$0.96
Dividend Yield:	0.83%
Dividend Growth:	0.00% (3 Year Average)
Payout Ratio:	11.96% (Trailing 12 Months of Earnings) 12.31% (Based on This Year's Estimates) 11.52% (Based on Next Year's Estimates)
Track Record:	2 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/12/2018	quarterly	$0.24	0.88%	3/28/2018	3/29/2018	4/30/2018
12/18/2017	quarterly	$0.24	0.79%	12/28/2017	12/29/2017	1/29/2018
8/7/2017	quarterly	$0.24	0.83%	9/21/2017	9/22/2017	10/27/2017
5/30/2017	quarterly	$0.24	0.81%	6/21/2017	6/23/2017	7/28/2017
3/1/2017	quarterly	$0.24	0.81%	3/29/2017	3/31/2017	4/28/2017
12/19/2016	quarterly	$0.24	0.94%	12/28/2016	12/30/2016	1/27/2017
8/23/2016	quarterly	$0.24	0.74%	9/21/2016	9/23/2016	10/28/2016
5/23/2016	quarterly	$0.24		6/22/2016	6/24/2016	7/29/2016
2/24/2016	quarterly	$0.24	0.99%	3/29/2016	3/31/2016	4/29/2016
12/14/2015	quarterly	$0.22	0.87%	12/29/2015	12/31/2015	1/29/2016
8/24/2015	quarterly	$0.22	0.9%	9/28/2015	9/30/2015	10/30/2015
5/5/2015	quarterly	$0.22	0.8%	5/13/2015	5/15/2015	7/14/2015
2/24/2015	quarterly	$0.22	0.73%	3/4/2015	3/6/2015	4/24/2015
12/15/2014	quarterly	$0.22	0.81%	12/24/2014	12/29/2014	1/30/2015
8/26/2014	quarterly	$0.22	0.87%	9/24/2014	9/26/2014	10/31/2014
5/23/2014	quarterly	$0.22	0.86%	6/25/2014	6/27/2014	7/25/2014
3/5/2014	quarterly	$0.22	0.9%	3/26/2014	3/28/2014	4/25/2014
12/16/2013	quarterly	$0.20	0.88%	12/24/2013	12/27/2013	1/31/2014
9/9/2013	quarterly	$0.20	0.99%	9/25/2013	9/27/2013	10/25/2013
6/14/2013	quarterly	$0.20	1.03%	6/26/2013	6/28/2013	7/26/2013
3/8/2013	quarterly	$0.20	1.06%	3/26/2013	3/29/2013	4/26/2013
12/14/2012	quarterly	$0.18	1.06%	12/24/2012	12/27/2012	1/25/2013

(Data available from 1/1/2013 forward)

Zimmer Biomet (NYSE ZBH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 86.28%

Insider Trading History for Zimmer Biomet (NYSE:ZBH)

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE ZBH) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2018	Bryan C Hanson	Insider	Buy	25,077	$119.68	$3,001,215.36
2/12/2018	Chad F. Phipps	VP	Sell	20,826	$115.95	$2,414,774.70
7/31/2017	Tony W. Collins	VP	Sell	16,986	$121.74	$2,067,875.64
6/12/2017	Sang Yi	Insider	Sell	17,731	$124.56	$2,208,573.36
5/5/2017	Chad F. Phipps	VP	Sell	6,200	$116.76	$723,912.00
4/27/2017	David C Dvorak	Insider	Sell	87,331	$116.47	$10,171,441.57	381,886
3/20/2017	David C Dvorak	Insider	Sell	1,040	$121.63	$126,495.20	294,077
12/2/2016	David A. Jr. Nolan	Insider	Sell	5,050	$101.11	$510,605.50
9/8/2016	Daniel E Williamson	Insider	Sell	2,716	$129.96	$352,971.36	2,000
8/23/2016	Stuart G Kleopfer	Insider	Sell	3,397	$129.71	$440,624.87	3,000
8/12/2016	Tony W. Collins	VP	Sell	1,287	$129.16	$166,228.92
8/9/2016	Stuart G Kleopfer	Insider	Sell	533	$132.71	$70,734.43	6,397
8/1/2016	David A. Jr. Nolan	Insider	Sell	25,255	$130.77	$3,302,596.35
7/11/2016	Daniel P Florin	CFO	Sell	15,000	$124.98	$1,874,700.00	16,983
6/14/2016	Tony W Collins	CAO	Sell	3,611	$116.43	$420,428.73	3,245
6/9/2016	Stuart G Kleopfer	Insider	Sell	11,000	$119.45	$1,313,950.00	7,609
4/14/2016	Daniel P Florin	CFO	Sell	10,000	$114.98	$1,149,800.00	28,415
4/12/2016	Daniel P Florin	CFO	Sell	12,000	$110.00	$1,320,000.00	38,415
3/21/2016	David C Dvorak	CEO	Sell	1,540	$104.16	$160,406.40	277,416
2/10/2016	Blackstone Capital Partners V	Major Shareholder	Sell	7,351,708	$95.91	$705,102,314.28
1/8/2016	David C. Dvorak	CEO	Sell	44,661	$102.46	$4,575,966.06	244,502
12/2/2015	David A. Jr. Nolan	insider	Sell	3,435	$102.62	$352,499.70	12,139
6/30/2015	Adam Rudolph Johnson	Insider	Sell	30,600	$110.34	$3,376,404.00
6/29/2015	Daniel E Williamson	Insider	Sell	16,000	$110.98	$1,775,680.00
6/29/2015	Daniel P Florin	CFO	Sell	5,000	$107.00	$535,000.00
3/17/2015	David C Dvorak	CEO	Sell	1,300	$115.55	$150,215.00
12/5/2014	David C Dvorak	CEO	Sell	48,703	$115.00	$5,600,845.00
11/28/2014	Chad F Phipps	VP	Sell	5,000	$112.00	$560,000.00
11/3/2014	Katarzyna Mazur-Hofsaess	Insider	Sell	28,253	$110.01	$3,108,112.53
9/9/2014	Stephen Hong Liang Ooi	Insider	Sell	40,768	$102.78	$4,190,135.04
8/26/2014	James T Crines	CFO	Sell	40,768	$101.00	$4,117,568.00
1/8/2014	Jeffery Mccaulley	Insider	Sell	21,286	$96.00	$2,043,456.00	5,211
1/7/2014	Chad Phipps	VP	Sell	7,000	$95.00	$665,000.00	17,240
12/20/2013	Jeffery Mccaulley	Insider	Sell	21,286	$93.00	$1,979,598.00	5,211
12/3/2013	Jeffery Mccaulley	Insider	Sell	2,713	$90.12	$244,495.56	5,211
11/15/2013	Derek Davis	CAO	Sell	3,500	$90.20	$315,700.00	2,791
11/14/2013	Chad Phipps	VP	Sell	7,800	$90.00	$702,000.00	17,240
11/14/2013	David Dvorak	CEO	Sell	64,763	$90.00	$5,828,670.00	172,746
11/14/2013	Jeffery Mccaulley	Insider	Sell	21,285	$90.00	$1,915,650.00	7,924
9/13/2013	Katarzyna Mazur-Hofsaess	Insider	Sell	4,890	$81.38	$397,948.20	1,643
8/1/2013	James T Crines	CFO	Sell	46,200	$84.56	$3,906,672.00
8/1/2013	Stephen Hong Liang Ooi	Insider	Sell	38,500	$84.27	$3,244,395.00
7/29/2013	Derek M Davis	CAO	Sell	3,725	$83.78	$312,080.50
7/29/2013	Jeffery A Mccaulley	Insider	Sell	112,255	$83.40	$9,362,067.00
7/19/2013	Chad F Phipps	VP	Sell	6,000	$83.00	$498,000.00
5/8/2013	Chad F Phipps	VP	Sell	5,000	$77.26	$386,300.00
4/30/2013	James T Crines	CFO	Sell	25,000	$76.08	$1,902,000.00
4/30/2013	Jeffery A Mccaulley	Insider	Sell	10,000	$76.08	$760,800.00
2/4/2013	Derek M Davis	CAO	Sell	21,864	$72.53	$1,585,795.92
2/4/2013	Jeffery A Mccaulley	Insider	Sell	12,000	$73.60	$883,200.00

(Data available from 1/1/2013 forward)

Zimmer Biomet (NYSE ZBH) News Headlines

Source:

Date	Headline
	Zimmer Biomet (ZBH) Expected to Post Earnings of $1.87 Per Share www.americanbankingnews.com - April 26 at 7:18 PM
	Zimmer Biomet Q1 revenues up 2%; updates guidance seekingalpha.com - April 26 at 5:01 PM
	Zimmer Biomet's (ZBH) CEO Bryan Hanson on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 26 at 5:01 PM
	Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop finance.yahoo.com - April 26 at 5:01 PM
	Zimmer Biomet (ZBH) Announces Quarterly Earnings Results www.americanbankingnews.com - April 26 at 4:36 PM
	Zimmer Biomet (ZBH) Issues FY18 Earnings Guidance www.americanbankingnews.com - April 26 at 11:19 AM
	Zimmer Biomet beats by $0.02, beats on revenue seekingalpha.com - April 26 at 8:36 AM
	Zimmer Biomet profit slides 42% www.marketwatch.com - April 26 at 8:36 AM
	Zimmer Biomet (ZBH) Beats on Q1 Earnings & Revenue Estimates finance.yahoo.com - April 26 at 8:36 AM
	Interesting ZBH Put And Call Options For December 21st www.nasdaq.com - April 25 at 5:12 PM
	Royal Bank of Canada Increases Zimmer Biomet (ZBH) Price Target to $140.00 www.americanbankingnews.com - April 20 at 6:24 PM
	Zimmer Biomet (ZBH) Earns Buy Rating from BMO Capital Markets www.americanbankingnews.com - April 19 at 5:50 PM
	Zimmer Biomet (ZBH) Upgraded to "Buy" by Guggenheim www.americanbankingnews.com - April 18 at 9:10 PM
	Oregon Surgical Institute to Implement Zimmer Biomet Signature Solutions Outpatient Program finance.yahoo.com - April 18 at 5:24 PM
	Consort Medical (CSRMY) vs. Zimmer Biomet (ZBH) Head-To-Head Comparison www.americanbankingnews.com - April 18 at 11:30 AM
	Zimmer Biomet (ZBH) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 2:28 AM
	VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer feeds.benzinga.com - April 17 at 8:13 PM
	FY2019 EPS Estimates for Zimmer Biomet (ZBH) Decreased by Leerink Swann www.americanbankingnews.com - April 17 at 6:51 AM
	Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes? finance.yahoo.com - April 16 at 5:02 PM
	Zimmer Biomet Announces FDA Clearance and First Surgical Case of the Persona® Trabecular Metal™ Tibia finance.yahoo.com - April 16 at 5:02 PM
	Zimmer Biomet (ZBH) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 15 at 6:59 AM
	Zimmer Biomet (ZBH) Stock Rating Reaffirmed by Canaccord Genuity www.americanbankingnews.com - April 12 at 9:35 PM
	Analysts Expect Zimmer Biomet Holdings Inc (ZBH) Will Announce Quarterly Sales of $1.98 Billion www.americanbankingnews.com - April 11 at 2:04 AM
	Zimmer Biomet (ZBH) Given a $137.00 Price Target by Oppenheimer Analysts www.americanbankingnews.com - April 10 at 5:37 PM
	Zimmer Biomet Holdings Inc (ZBH) Expected to Post Earnings of $1.87 Per Share www.americanbankingnews.com - April 9 at 9:20 PM
	Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope finance.yahoo.com - April 9 at 5:02 PM
	Zimmer Biomet (ZBH) Earns "Buy" Rating from SunTrust Banks www.americanbankingnews.com - April 8 at 4:51 PM
	Why Trump's Tariffs Could Raise the Cost of a Hip Replacement www.nytimes.com - April 7 at 9:01 AM
	MSA Safety (MSA) and Zimmer Biomet (ZBH) Critical Contrast www.americanbankingnews.com - April 5 at 1:20 AM
	Zimmer Biomet Holdings (ZBH) Reports FDA Clearance of Comprehensive Augmented Baseplate for Shoulder Reconstruction www.streetinsider.com - April 3 at 8:51 AM
	Zimmer Biomet (ZBH) Research Coverage Started at Evercore ISI www.americanbankingnews.com - April 2 at 5:18 PM
	Zimmer Biomet Announces FDA Clearance of the Comprehensive® Augmented Baseplate for Shoulder Reconstruction finance.yahoo.com - April 2 at 5:07 PM
	Zimmer Biomet (ZBH) Cut to Neutral at Piper Jaffray www.americanbankingnews.com - April 2 at 8:18 AM
	Zimmer Biomet (ZBH) Price Target Lowered to $125.00 at Royal Bank of Canada www.americanbankingnews.com - April 1 at 3:42 PM
	Zimmer Biomet (ZBH) Raised to "Buy" at Edward Jones www.americanbankingnews.com - March 31 at 6:34 PM
	Zimmer Biomet's Mobi-C Cervical Disc shows maintains benefit in long-term study seekingalpha.com - March 29 at 5:09 PM
	Zimmer Biomet Spine Announces Mobi-C® Cervical Disc Seven-Year Follow-Up Data Published in International Journal of Spine Surgery finance.yahoo.com - March 29 at 8:54 AM
	Zimmer Biomet (ZBH) Upgraded to "Buy" at ValuEngine www.americanbankingnews.com - March 28 at 7:05 PM
	Zimmer Biomet Joins U.S. Department of Energy's Better Buildings, Better Plants Program finance.yahoo.com - March 27 at 8:58 AM
	Robert W. Baird Reaffirms "Buy" Rating for Zimmer Biomet (ZBH) www.americanbankingnews.com - March 26 at 12:14 PM
	Stifel Nicolaus Upgrades Zimmer Biomet (ZBH) to "Buy" www.americanbankingnews.com - March 26 at 11:35 AM
	$1.98 Billion in Sales Expected for Zimmer Biomet Holdings Inc (ZBH) This Quarter www.americanbankingnews.com - March 25 at 2:18 AM
	Zimmer Biomet (ZBH) Lowered to Hold at ValuEngine www.americanbankingnews.com - March 23 at 10:14 PM
	Zimmer Biomet Holdings Inc (ZBH) Expected to Announce Earnings of $1.88 Per Share www.americanbankingnews.com - March 23 at 7:24 PM
	Robert W. Baird Lowers Zimmer Biomet (ZBH) to Neutral www.americanbankingnews.com - March 23 at 6:49 PM
	Zimmer Biomet Holdings Announces Audio Webcast and Conference Call of First Quarter 2018 Results finance.yahoo.com - March 22 at 5:15 PM
	Zimmer Biomet Holdings Inc (ZBH) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 21 at 5:34 AM
	Zimmer Biomet Appoints Coleman N. Lannum as Senior Vice President of Investor Relations finance.yahoo.com - March 19 at 4:56 PM
	German defence ministry seeks continuity with new procurement chief finance.yahoo.com - March 16 at 6:06 PM
	Zimmer Biomet (ZBH) Coverage Initiated at Oppenheimer www.americanbankingnews.com - March 15 at 7:06 PM

Zimmer Biomet (NYSE:ZBH) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Zimmer Biomet (NYSE:ZBH) Income Statement, Balance Sheet and Cash Flow Statement

Zimmer Biomet (NYSE ZBH) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff